BioLineRx (BLRX) Q3 2025 earnings summary

Executive summary

• Formed a joint venture with Hemispherian to develop GLIX1, a first-in-class oral small molecule targeting glioblastoma and other cancers, with a phase I/II-A trial set to begin in Q1 2026 and leveraging complementary expertise in clinical development and small molecule discovery.

• GLIX1's IND was cleared by the FDA in August, with initial phase 1 data expected in H1 2027.

• Retained rights to develop metixafortide in pancreatic cancer (PDAC) and continue to support its development through the CheMo4METPANC phase II-B trial in collaboration with Columbia University and Regeneron.

• Maintains a cash runway into the first half of 2027, with $25.2 million in cash and equivalents as of September 30, 2025.

Financial highlights

• Q3 2025 total revenues were $0.4 million, reflecting royalties from APHEXDA commercialization.

• Research and development expenses were $1.7 million, down from $2.6 million in Q3 2024, mainly due to lower metixafortide-related costs, out-licensing, and reduced headcount.

• No sales and marketing expenses in Q3 2025, compared to $5.5 million in Q3 2024, following the shutdown of U.S. commercial operations.

• General and administrative expenses were $0.8 million, down from $1.4 million year-over-year.

• Net loss for Q3 2025 was $1 million, compared to $5.8 million in Q3 2024.

Outlook and guidance

• GLIX1 phase I/II-A trial in glioblastoma to start in Q1 2026, with phase 1 data anticipated in H1 2027 and potential periodic updates before then.

• Plans to expand GLIX1 development into additional cancer indications after establishing safety and dosing.

• Ongoing support for metixafortide in PDAC and sickle cell disease, with key data presentations expected at upcoming conferences and interim analysis planned at 40% PFS events.

• Cash runway expected to last into the first half of 2027.